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Abstract
The work presented herein describes the first comprehensive analysis of a partially deglycosylated
HIV vaccine candidate envelope protein (Env). The Env, JRFL gp140 ΔCF, with 27 potential
glycosylation sites, was partially deglycosylated with PNGase F as part of a strategy to generate a
more immunogenic HIV vaccine, and the resulting protein’s glycosylation was characterized in a
unique workflow using two different glycosidases, Endo H and Endo F3. This unique analysis
protocol provided for coverage on 26 of the 27 glycosylation sites, and the data showed that the
biochemical treatment with PNGase F resulted in a highly heterogeneous glycoprotein product
that had been partially deglycosylated at most of the glycosylation sites. The protocols described
in this work could be useful for characterizing the glycosylation site occupancy of other native or
biochemically deglycosylated proteins.
Introduction
Glycoproteins are an important and growing class of biopharmaceuticals. Currently,
glycoprotein-based pharmaceuticals are used or under development for solving a broad
variety of health problems, including low fertility [1], renal failure [2], or to prevent the
transmission of HIV [3,4]. The glycosylation on proteins is often necessary to assure proper
protein folding, especially during protein expression. However, the glycosylation can also
have detrimental effects, such as targeting the protein for excretion[5,6], or suppressing the
protein’s intended function [7].
One poignant example of the deleterious effects of glycosylation is found in the hunt for an
HIV vaccine. The glycans on Env, the protein on the surface of the HIV virus which is
expressed in mammalian cells and used in vaccine trials, cover immunogenic epitopes of the
protein [8] and may also suppress the immune system by binding to carbohydrate receptors
on T cells [9–11]. Unfortunately, Env, like many proteins, requires the glycans to be present
during protein folding.[12,13]Otherwise, unfolded, inactive protein is produced.
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One possible strategy to generating better biopharmaceuticals, such as a more effective HIV
vaccine, would be to express a well-folded glycoprotein of interest with its glycosylation
intact, then either fully or partially remove the glycans under non-denaturing conditions,
using an enzyme such as peptide N-glycosidase (PNGase F). This strategy is currently being
explored as a means to develop an effective HIV vaccine [14]. A key limitation of this
strategy is that significant efforts must be undertaken to characterize the partially
deglycosylated species, so that the proteins’ change in function can be related back to its
modified composition. Characterizing the remaining glycosylation on a protein such as HIV
Env is a quite burdensome process. Fully glycosylated Env proteins require at least 200 µg
of protein at >4 mg/mL for full glycosylation site-specific analysis [15,16], and
heterogeneous mixtures of glycosylated and deglycosylated proteins would likely result in
an increase in this sample requirement. In addition to sample consumption issues, analyzing
glycosylation in a glycosylation site-specific manner is quite a labor and skill intensive
process [17], where a single protein could take months to analyze. Therefore, instead of
charactering the remaining glycosylation on Env, which would be quite burdensome, we
introduce a new analytical platform to rapidly characterize these species using a
complementary approach. In this platform, partially deglycosylated proteins are treated with
endoglycosidases (Endo H and Endo F3) to reduce the complexity of the remaining N-linked
glycopeptides, and the products are detected by LC/MS and MS/MS. The glycosidases
cleave the glycans between the first and second N-acetylhexosamine in the N-linked core,
leaving a single N-acetylhexosamine attached to the peptide (Figure 1) [18–20]. The
advantages of the endoglycosidase treatment at least two-fold: 1) The resulting
glycopeptides (with the single HexNAc attached) are quite simple to characterize because
the glycan mass is known; therefore, the exact mass of the glycopeptide is known, and the
glycosylated peptides can be searched for and identified in an automated fashion. 2) Since
all heterogeneity of the glycan component is clipped off, the MS signal is stronger because
all the heterogeneous glycans with different m/z’s now produce one product, with a single m/
z. This results in lower detection limits and lower sample requirements for the analysis. It is
important to note however, that if glycoproteins are partially core-fucosylated, two peaks,
instead of one, may be detected.
While endoglycosidases have been used previously to characterize the natural site
occupancy of a protein [21–23], this is the first example of using these enzymes in a rapid
and reliable method to determine which glycosylation sites on a glycoprotein have been
deglycosylated by another enzyme, PNGase F, and detailed information is provided about
every glycosylation site in the protein of interest. The analysis of one HIV envelope vaccine
candidate, HIV Env JRFL gp140 ΔCF, with 27 potential glycosylation sites, is used to
demonstrate the utility of the method. The method developed herein could be applied
broadly to other glycosylated HIV vaccine candidates or to any other protein whose
glycosylation is fully or partially removed.
Experimental Section
Reagents
Trizma@ hydrochloride, Trizma@ base, ethylenediaminetetraacetic acid (EDTA), glacial
acetic acid, HPLC grade acetonitrile (CH3CN) and methanol (CH3OH), hydrochloric acid,
ammonium acetate, sodium acetate, ammonium hydroxide, insulin from bovine pancreas,
iodoacetamide (IAA), dithiothreitol (DTT), and formic acid were purchased from Sigma (St.
Louis, MO). Water was purified using a Millipore Direct-Q3 Water Purification System
(Billerica, MA). Sequencing grade trypsin (Tp) and endoproteinase Glu-C from
Staphylococcus aureus V8 were obtained from Promega (Madison, WI) and Sigma (St
Louis, MO), respectively. Glycerol-free peptide N-glycosidase (PNGase F) from
Flavobacterium meningosepticum, endo-β-N-acetylglucosaminidase H (Endo H), and endo-
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β-N-acetylglucosaminidase F3 (Endo F3) from Elizabethkingia meningosepticum from
Streptomyces plicatus, were obtained from New England BioLabs (Ipswich, MA), and EMD
Biosciences (Gibbstown, NJ).
Expression and Purification of HIV-1 Subtype B Envelope Proteins
Recombinant JRFL gp140 ΔCF envelope protein was obtained from the Duke Human
Vaccine Research Institute in Durham N.C. The envelope protein was constructed with
internal deletions and was expressed and purified as described previously [24,25]. Briefly,
recombinant vaccinia viruses (rVVs) expressing JR-FL gp140 ΔCF were used for
production of soluble oligomeric envelope protein. Batch production was carried out by
infecting 293T cells with rVVs. The 293T cells were cultured in Dulbecco modified Eagle
medium (DMEM; Invitrogen Corp, Carlsbad, CA) supplemented with 10% fetal calf serum
in T150 tissue culture flasks and were grown to confluence at a multiplicity of infection
(MOI) of about one before infecting with rVVs. At two hours post-infection, the cell culture
was washed with serum free DMEM and the infection was allowed to proceed for 72 hours.
Recombinant JR-FL gp140 ΔCF was purified from supernatants of rVV-infected 293T cell
cultures using Galanthus nivalis lectin-agarose (Vector Labs, Burlingame, CA) column
chromatography and stored at −70°C until use [16,24–27]. A typical batch production using
30 T-150 TC flasks would yield 1–3 mg of purified recombinant HIV-1 envelope protein.
Protein concentration was determined by absorbance. Purified recombinant envelope
proteins were concentrated for MS-based glycosylation analysis.
Partial N-Deglycosylation of the Envelope Protein
Glycans were removed partially by incubating 100 µg of the envelope protein with 4.0 µL
PNGase F (2,000 U) under non-denaturing conditions. The reaction mixture (200 µL) was
incubated at 37°C for 24 hours and was stopped by freezing at −70°C and was stored at this
temperature prior to analysis.
Endo H and Endo F3 Deglycosylation of Envelope Proteins
Deglycosylated envelope proteins were either treated with Endo H or Endo F3. These
enzymes cleave between the N-acetylglucosamine residues in the chitobiose core of N-
linked glycans leaving an N-acetylglucosamine or N-acetylglucosamine with fucose on the
asparagine residue. Endo H is specific for high mannose and hybrid glycans while Endo F3
is specific for complex glycans. Typical deglycosylation with these endoglycosidases was
performed by incubating ~7 fmol of the envelope protein (protein concentration of ~7 mg/
mL) with the enzyme solutions ( ≥ 30 units/mg protein). For the Endo H deglycosylation
experiment, the sample was denatured with 2 M urea in 100 mM tris buffer (pH 5.5)
followed by the addition of 2 µL of Endo H. After thorough mixing, the reaction was
incubated for 48 hours at 37°C. For the Endo F3 deglycosylation experiment, samples were
incubated with ~6 µL of 250 µM NH4C2H2O2 (pH 4.5) and 2 µL of Endo F3 for two weeks
at 37°C. Endo H and Endo F3 treated deglycosylated envelope protein were either digested
with trypsin or GluC as described below. As a control, native envelope protein was treated
with Endo H and Endo F3 as described above and then subsequently digested with trypsin or
endoproteinase Glu-C.
Digestion of envelope proteins
Samples containing 75 µg of the HIV-1 envelope protein, with protein concentration ~7 mg/
mL, were denatured with 6M urea and digested with trypsin or endoproteinase Glu-C. The
proteins were reduced and alkylated with 10 mM DTT and 15 mM IAA at RT, respectively.
Protein digestion with trypsin was performed at a protein:enzyme ratio of 30:1 (w/w) in 100
mM tris buffer (pH 8.5) containing 3 mM EDTA while protein digestion with
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endoproteinase Glu-C was performed at a protein:enzyme ratio of 20:1 (w/w) in 100 mM
tris buffer (pH 7.8) containing 3 mM EDTA. Digestion was allowed to proceed overnight at
37°C and was stopped with the addition of 1 µL of glacial acetic acid. The resulting HIV
envelope glycoprotein digest was analyzed by RP-HPLC/ESI-FTICR MS. Protein digestion
was performed three times on different days with samples obtained from the same batch to
ensure reproducibility and reliability of the method.
Mass Spectrometry
LC/ESI-FTICR MS experiments were performed using a hybrid linear ion-trap Fourier
transform ion cyclotron resonance mass spectrometer (LTQ-FT, ThermoScientific, San Jose,
CA) directly coupled to a Dionex UltiMate capillary LC system (Sunnyvale, CA) equipped
with a FAMOS well plate autosampler. Mobile phases utilized for the experiment consisted
of solvent A: 99.9% deionized H2O + 0.1% formic acid and solvent B: 99.9 % CH3CN +
0.1% formic acid. Five microliters of the digested sample was injected onto C18 PepMap™
300 column (300 µm i.d. × 15 cm, 300 Å, LC Packings, Sunnyvale, CA) at a flow rate of 5
µL/min. The following CH3CN/H2O multistep gradient was used: 5% mobile phase B for 5
min, followed a linear increase to 40% B in 50 min a linear increase to 90% B in 10 min.
The column was held at 95% B for 10 minutes before re-equilibration. A short wash and
blank run were performed between every sample to ensure no sample carry-over. The ESI
source was operated in the following conditions: source voltage of 2.8 kV, capillary
temperature of 200 °C, and capillary voltage of 46 V. ESI source parameters were optimized
for maximum sensitivity using 100 nM insulin at m/z 1147.70. Data were collected in a data-
dependent mode in which the five most intense ions in an FT scan were sequentially and
dynamically selected for subsequent collision-induced dissociation (CID) in the LTQ linear
ion trap using a normalized collision energy of 30% and a 3 minute dynamic exclusion
window.
Peptide Identification
Glycopeptides and Deglycosylated peptides were identified by searching raw MS/MS data
acquired on the hybrid LTQ FTICR mass spectrometer against a custom HIV database with
127 protein entries, obtained from the Los Alamos HIV sequence database
(http://www.hiv.lanl.gov/content), using Mascot (Matrix Science, London, UK, version
2.2.04). The peak list was extracted from raw files and converted to mgf files using
DTAsupercharge v. 1.18. Mgf files were searched against the custom HIV database
specifying the following parameters: (a) enzyme: trypsin or V8-E, (b) missed cleavage: 2,
(c) fixed modification: carbamidomethyl, (d) variable modification: methionine oxidation,
carbamyl, pyro-carbamidomethyl, Gln-> pyro-Glu, HexNac, and HexNac(1)dHex(1)(N) (e)
peptide tolerance of 0.8 Da, and (f) MS/MS tolerance of 0.4 Da. Deglycosylated peptides
identified from Mascot search were manually validated from MS/MS spectra to ensure
major fragmentation ions (b and y ions) were observed especially for deglycosylated




The glycoprotein used in these studies, JRFL gp140 ΔCF, is an Env immunogen grown in
293T cells (Figure 2). The protein has 27 unique potential N-linked glycosylation sites
(highlighted in red), and we have previously shown that the glycans at these sites are a
heterogeneous mix of various types of processed and high mannose glycans [15].
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The ultimate goal of this study was to develop methods to characterize the partially
deglycosylated form of this Env using the enzyme PNGase F. Therefore, the primary
objective is to identify when glycosylation is present (and when it has been removed) at each
glycosylation site on the protein. The experimental protocol in Figure 3 describes how
glycosylation removal is detected.
Fully glycosylated sample: Each site is detected
Prior to analyzing deglycosylated proteins, control experiments on the fully glycosylated
protein were conducted. The purpose of these experiments was to verify that full coverage of
the glycosylation sites was obtained on a protein that had not been deglycosylated. (These
experiments were designed to prove that if a peptide was glycosylated, the method described
herein would detect it.)
In these experiments, the protein, JRFL gp140 ΔCF, was subjected to two separate
glycosidase reactions, one with Endo H and the other with Endo F3, as displayed in Figure
3, and the deglycosylated products were subjected to tryptic digestion and Glu-C digestion
and LC-MS/MS analysis. The expected outcome of these experiments are as follows: After
treatment with Endo H, each glycosylation sites known to have high mannose glycans
present should be detected as a glycopeptide containing a single N-acetylhexosamine at the
glycosylation site. Similarly, after treatment with Endo F3, each glycopeptide that is known
to have complex glycans present at the glycosylation site should be detected as a peptide
with an N-acetylhexosamine (with or without an additional attached fucoses).
An example of the LC/MS data for the glycopeptides produced after one of the
endoglycosidase experiments on the fully glycosylated JRFL Env protein is shown in Figure
4. The top panel (4A) is the HPLC chromatogram, with one segment of the chromatogram
highlighted. Panel 4B shows the MS data for this time window. The peak at m/z 1342
corresponds to a glycopeptide that contains the peptide sequence
NVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIR plus a single N-acetylhexosamine at
each of the two glycosylation sites (in bold). The composition of this glycopeptide is
verified by MS/MS experiments, as shown in Figure 4C.
After LC/MS/MS analysis of the protein digested with endoglycosidase and trypsin, a high
level of sequence coverage was obtained. The characterized fully glycosylated Env JRFL
peptides are listed in Table 1. Every glycosylation site on the protein is represented in the
data as a tryptic peptide, with the exception of a segment of the protein in the V4 loop. The
tryptic peptide corresponding to this segment is quite large. With no missed cleavages, the
peptide would be:
TIVFNHSSGGDPEIVMHSFNCGGEFFYCNSTQLFNSTWNNNTEGSNNTEGNTITLPC
R. Since this peptide is not detected as a tryptic peptide, we digested the deglycosylated
protein with Glu-C, in a separate experiment. This enzyme produces slightly smaller
peptides for this region: NKTIVFNHSSGGDPE and
IVMHSFNCGGEFFYCNSTQLFNSTWNNNTEGSNNTE. Both the smaller peptides were
detected in the Glu-C digestion, affording 100% sequence coverage of the glycosylation
sites on the protein. Both of these peptides appear in Table 1.
These data demonstrate that the endoglycosidase conditions described here successfully
identify when glycosylation is present on the glycopeptide. Additionally, the use of both
glycosidase enzymes (Endo H and Endo F3) is important if one does not know the type of
glycosylation on the protein in advance, since the enzymes are selective for only certain
classes of glycans. While enzyme selectivity can be a disadvantage in that two separate
experiments must be conducted, the selectivity is also an advantage because these
experiments provide some information about the types of glycans that are present at each of
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the glycosylation site, without having to do an intense glycopeptide analysis of the fully
glycosylated protein.
Partially Deglycosylated HIV JRFL Envelope
After successfully demonstrating that the experiments outlined in Figure 3 provided 100%
coverage of the glycosylation sites, we applied this same methodology to the same protein,
that first had been partially deglycosylated with PNGase F, to show that the method could be
used to track that sites had been deglycosylated under non-denaturing conditions. For this
deglycosylated protein, the exact level of remaining glycosylation was unknown, however,
the protein’s dramatic decrease in molecular weight (as observed by SDS-PAGE) suggested
that a significant fraction of the glycans had been removed (not shown) [14] .
To analyze this partially deglycosylated Env, the same experimental protocol as described in
Figure 3 was used, and all of the species that had been identified in Table 1 were searched
for in the new data set. When the ions in Table 1 are also present in the new data set, this
indicates that the glycosylation sites corresponding to these ions still have glycans attached.
In addition to searching for these species, deglycosylated peptides were also searched for
and identified. The fully deglycosylated peptides, generated by PNGase F treatment, convert
the N (Asn) at the glycosylation site to D (Asp), concomitant with glycan removal, as
described in Figure 1. Therefore, glycosylation sites that have been deglycosylated are
identified by detecting the peptide sequences with N to D conversion at the glycosylation
sites. It is important to note that while it is possible for proteins to naturally undergo an N to
D conversion at potential glycosylation sites when the asparagines are not glycosylated, this
problem is not relevant here because we probed for such unusual modifications in the fully
glycosylated protein, and found no such instances of this modification. Therefore, any
peptides undergoing N to D conversion at a glycosylation site can be confidently identified
as a site on the protein that has been deglycosylated.
For peptides with a single glycosylation site, the process of identifying whether or not
PNGase F cleaved some or all the glycans is straightforward. For these peptides, one simply
searches for the peptide undergoing N to D conversion, (to identify deglycosylated peptides)
and the peptide containing one HexNAc at the glycosylation site (to identify cases where
glycan is still attached). The analysis is slightly more complicated when a single tryptic
peptide contains multiple glycosylation sites, since each site could be glycosylated or
deglycosylated. As an example, the peptide ESVEINCTRPNNNTR could be present in 4
different forms, either as ESVEIN (HexNAc)CTRPNN (HexNAc)NTR, ESVEIDCTRPNN
(HexNAc)NTR, ESVEIN (HexNAc)CTRPNDNTR, or ESVEIDCTRPNDNTR. While two
of these peptides are uniquely identifiable based on their mass, the remaining two
glycoforms are only distinguishable by MS/MS analysis. The LC-MS/MS data was searched
for each possible form of each peptide, and MS/MS data was used to confirm each of the
assignments. Figure 5 shows an example of the MS and MS/MS data for one of the
glycopeptides with two glycosylation sites. Tandem mass spectrometry experiments must be
used in this case to distinguish which site is deglycosylated and which site still contains a
HexNAc.
After a thorough analysis of the partially deglycosylated Env protein, the results were
compiled in Table 2. By coupling data from the tryptic digests with data from the Glu-C
digest, all of the glycosylation sites except one were detected. The missing site is the final
glycosylated Asn in the V4 loop. In the sample which was not treated with PNGase F, this
site was only detected on a peptide with a missed cleavage, containing the sequence,
VMHSFNCGGEFFYCNSTQLFNSTWNNNTEGSNNTE (See Table 1). In the data for the
PNGase F treated sample, this peptide was not detected. Instead, the shorter peptide,
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containing no missed cleavages, FFYCNSTQLFNSTWNDNTE, was detected. This shorter
peptide lacks the fourth glycosylation site, GSNNTE.
For the 26 of 27 glycosylation sites that were detected, virtually all of them were detected as
either fully deglycosylated peptides or mixtures of fully and partially deglycosylated
species. The large peptide in the C3-V4 region was the only species that was not detected at
some level, as a fully deglycosylated glycoform. This peptide was the most difficult to
detect species in the entire Env protein, so it is possible that a fully deglycosylated form of
this species was present, but below our method’s detection limit. Interestingly, the
glycosylation sites at the N- and C-terminus of the protein were exclusively deglycosylated;
these were likely most accessible to PNGase F. All other sites in the protein were detected as
at least partially glycosylated (and therefore, only partially deglycosylated).
While the apparent molecular weight (from SDS-PAGE) of the PNGase F treated protein
suggests that this protein is heavily deglycosylated, the mass spectrometry data shows that
deglycosylation for this protein does not occur in a one-site-at-a-time manner. Instead, all of
these sites must be at least somewhat accessible to PNGase F, although the extent of
accessibility likely varies. Future analyses of samples that have been deglycosylated to
different extents could be useful in revealing which areas of the protein are most accessible
to PNGase F and, therefore, most accessible to antibodies. Additionally, quantitative
analyses, using label free methods or isotopically labeled internal standards, would allow
additional insights into how much deglycosylation had occurred at each site. Testing of the
efficacy of these vaccines is also ongoing, and those results will be published separately.
Conclusion
The data presented herein show the following: The experimental protocol in Figure 3 can be
used to verify when glycosylation is present on glycoproteins. The protocol accurately
identified the presence of high mannose and complex glycans present on all the occupied
glycosylation sites for the protein studied here. This protocol can also be used to
characterize proteins that have been partially deglycosylated with PNGase F. When the
protein is partially deglycosylated, both the deglycosylated species and their glycosylated
counterparts can be detected in the same experiment. These studies were used to chemically
characterize a potential HIV vaccine candidate that has been partially deglycosylated, and
these studies show that partial deglycosylation of Env proteins produces a highly
heterogeneous product, with most sights being partially deglycosylated.
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(A) Deglycosylation reaction with PNGase F. Both high mannose and complex glycans are
cleaved by the enzyme. Concomitant with glycan cleavage, the N at the glycosylation site is
converted into D. (B) Glycosidic cleavage reaction with Endo H. (C) Glycosidic cleavage
reaction with Endo F3.
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Sequence of the HIV Envelope protein, JRFL gp140ΔCF, used in these studies. All the
potential N-linked glycosylation sites are in red.
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Workflow for these studies. After treatment with PNGase F to deglycosylate the protein, the
sample is split and treated with Endo H and Endo F3. Each of these samples are then treated
with Trypsin and Glu-C, then analyzed by LC-MS.
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(A) Base peak chromatogram of the tryptic digest from the native JRFL gp140 ΔCF. A peak
at around 39 minutes is highlighted, and the MS data for this portion of the chromatogram is
shown in (B). The spectrum in (C) is the MS/MS data of the peak at m/z 1342, highlighted in
B.
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(A) MS data showing a peptide with two glycosylation sites. This peptide is detected as a
fully deglycosylated species (m/z 903) and a partially deglycosylated species (m/z 1004.)
The location of the remaining glycosylation site on m/z 1004 is determined using the MS/
MS data in (B). This spectrum shows abundant b/y cleavages and verifies that the first of the
two glycosylation sites is occupied with a glycan.
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